```html

Focal Nodular Hyperplasia (FNH) – A Patient‑Friendly Medical Guide

Overview

Focal Nodular Hyperplasia (FNH) is a benign (non‑cancerous) liver tumor that consists of a proliferation of normal liver cells (hepatocytes) arranged around a central scar. It is the second most common benign liver lesion after hepatic hemangioma.

• Who it affects: Predominantly women (about 80–90% of cases) and most commonly diagnosed in people aged 20–50 years.
• Prevalence: Autopsy and imaging studies suggest FNH occurs in 0.4–3% of the general population. In women using oral contraceptives, the prevalence can rise to ≈1% (Mayo Clinic, 2023).
• Nature of the lesion: FNH does not invade surrounding tissue, does not metastasize, and rarely causes symptoms. Because it is usually discovered incidentally during imaging for another reason, most patients remain asymptomatic throughout life.

Symptoms

Although most people with FNH feel fine, a minority may notice the following:

• Abdominal discomfort or dull pain – typically in the right upper quadrant where the liver sits.
• Fullness or a sense of pressure – especially after meals.
• Palpable liver edge – a small bump may be felt under the ribs in some cases.
• Unexplained weight loss – very uncommon; usually points to another condition.
• Fatigue – nonspecific, often related to an unrelated condition.
• Jaundice – rare; when present, clinicians first think of other liver diseases.
• Bleeding – extremely rare; FNH lesions are vascular, but they rarely rupture.

Because symptoms overlap with many other liver or gastrointestinal disorders, imaging is essential for a definitive diagnosis.

Causes and Risk Factors

What causes FNH?

The exact cause remains uncertain, but research suggests a vascular (blood‑flow) abnormality that leads to a localized over‑growth of normal liver tissue. The central scar usually contains a malformed artery that drives the hyperplasia.

Identified risk factors

• Female sex – Hormonal influences are thought to play a role.
• Oral contraceptive use – Long‑term use (>5 years) is associated with a modest increase in incidence, though the relationship is weaker than for liver adenomas.
• Pregnancy – Hormonal changes may enlarge an existing FNH, but most lesions remain stable.
• Underlying vascular anomalies – Rare congenital or acquired conditions affecting hepatic blood flow.
• Age 20–50 years – The majority of diagnosed cases fall within this window.

Diagnosis

Because FNH is rarely symptomatic, it is usually discovered incidentally during imaging for another issue (e.g., gallstones, fatty liver). The diagnostic pathway aims to differentiate FNH from other liver lesions, especially hepatocellular carcinoma (HCC) and liver adenoma.

Imaging studies

• Ultrasound (US) – First‑line; FNH often appears as a well‑defined, isoechoic or slightly hyperechoic lesion with a central scar that may be hypoechoic.
• Contrast‑enhanced CT scan – Shows a homogeneous arterial phase enhancement with a “spoke‑wheel” pattern and delayed central scar enhancement.
• Magnetic Resonance Imaging (MRI) with liver‑specific contrast (e.g., gadoxetate‑disodium) – The most accurate test. FNH typically displays intense arterial uptake, iso‑ or hyper‑intensity on T2‑weighted images, and a central scar that is hyperintense on T2 and enhances in the delayed phase.
• Contrast‑enhanced ultrasound (CEUS) – Useful when CT or MRI are contraindicated (e.g., renal insufficiency).

Biopsy

Needle biopsy is rarely required (< 5% of cases) because imaging features are usually distinctive. When performed, histology shows:

• Normal‑appearing hepatocytes arranged in lobules.
• A central fibrous scar containing abnormal blood vessels.
• Absence of cellular atypia or significant proliferation (rules out cancer).

Laboratory tests

Blood work is typically normal. Liver function tests (ALT, AST, ALP, bilirubin) are often within reference range, helping to exclude active liver disease. Tumor markers such as α‑fetoprotein (AFP) are not elevated in FNH.

Treatment Options

Because FNH is benign and usually asymptomatic, most patients do not need active treatment. Management is individualized based on symptoms, lesion size, growth, and patient preference.

Observation (watchful waiting)

• Regular imaging – Typically an ultrasound or MRI every 12–24 months for the first few years; then spacing out if stability is confirmed.
• Symptom monitoring – Patients keep a diary of any new pain or fullness.

Medical management

• Discontinuation or modification of oral contraceptives – May stabilize or slightly reduce lesion size; discussed with the prescribing clinician.
• Hormonal therapy – Not routinely recommended; evidence does not support benefit.

Interventional procedures

Reserved for rare cases with persistent pain, lesion growth, or diagnostic uncertainty.

• Radiofrequency ablation (RFA) – Small lesions (< 3 cm) can be destroyed percutaneously.
• Laparoscopic or open resection – Surgical removal is considered when the lesion causes significant symptoms, enlarges substantially (> 5 cm) or mimics a malignant tumor.
• Embolization – Rarely used; blocks arterial supply to shrink the lesion.

Lifestyle recommendations

• Maintain a balanced diet low in saturated fats and high in fruits, vegetables, and whole grains.
• Avoid excessive alcohol intake (< 2 drinks/day for women, < 3 for men) to protect overall liver health.
• Stay physically active – at least 150 minutes of moderate aerobic exercise per week.
• Discuss any hormonal therapy (including birth control) with your physician.

Living with Focal Nodular Hyperplasia

Daily management tips

• Know your lesion – Keep a copy of imaging reports showing size and characteristics.
• Schedule follow‑up – Mark your calendar for recommended imaging appointments.
• Listen to your body – If you develop new right‑upper‑quadrant pain, bloating, or unexplained fatigue, contact your provider.
• Medication safety – Inform all prescribers that you have FNH, especially before receiving contrast‑enhanced studies or hepatotoxic drugs.
• Pregnancy planning – Discuss potential lesion growth with your OB‑GYN; most pregnancies proceed without complications.

Emotional well‑being

Finding a “tumor” can be stressful, even when benign. Support groups, counseling, or patient‑advocacy websites (e.g., American Liver Foundation) can provide reassurance and up‑to‑date information.

Prevention

Because the precise cause is unknown, prevention focuses on modifiable risk factors:

• Use the lowest effective dose of oral contraceptives and consider non‑hormonal alternatives if you have a personal or family history of liver lesions.
• Limit alcohol to protect overall liver health.
• Maintain a healthy weight – Obesity can worsen fatty liver disease, which may complicate the interpretation of imaging.
• Vaccinate against hepatitis A and B to prevent superimposed liver disease.

Complications

Complications from FNH are rare, but clinicians remain vigilant for:

• Lesion growth – Large lesions (> 5 cm) may cause mechanical discomfort.
• Bleeding – Very uncommon; would present as sudden abdominal pain and signs of internal bleeding.
• Diagnostic confusion – Misidentifying FNH as malignant could lead to unnecessary surgery.
• Co‑existing liver disease – If a patient also has hepatitis, cirrhosis, or fatty liver, overall liver function may decline independent of FNH.

When to Seek Emergency Care

Key Take‑aways

• FNH is a benign liver lesion most common in women aged 20‑50 years.
• It is usually discovered incidentally and rarely causes symptoms.
• High‑resolution MRI with liver‑specific contrast is the gold‑standard for diagnosis.
• Management is typically observation; surgery is reserved for symptomatic or growing lesions.
• Maintaining overall liver health and discussing hormonal contraception with your provider are sensible preventative steps.

---

References

1. Mayo Clinic. “Focal Nodular Hyperplasia.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/focal-nodular-hyperplasia
2. American College of Radiology. “ACR Appropriateness Criteria – Liver Masses.” 2022.
3. Lee SS, et al. “Imaging features of focal nodular hyperplasia.” *Radiology*. 2021;298(3):621‑632.
4. Cleveland Clinic. “Focal Nodular Hyperplasia (FNH) of the Liver.” 2022.
5. World Health Organization. “Guidelines for the Management of Benign Liver Tumors.” 2020.
6. National Institutes of Health. “Liver Tumors – Benign vs Malignant.” 2023.

```